PT2726507T - Anticorpos contra antigéneos celulares especificos da próstata e uso dos mesmos - Google Patents
Anticorpos contra antigéneos celulares especificos da próstata e uso dos mesmosInfo
- Publication number
- PT2726507T PT2726507T PT12729996T PT12729996T PT2726507T PT 2726507 T PT2726507 T PT 2726507T PT 12729996 T PT12729996 T PT 12729996T PT 12729996 T PT12729996 T PT 12729996T PT 2726507 T PT2726507 T PT 2726507T
- Authority
- PT
- Portugal
- Prior art keywords
- stem cell
- antibodies against
- cell antigen
- specific stem
- against prostate
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000002307 prostate Anatomy 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pregnancy & Childbirth (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011118022.6A DE102011118022B4 (de) | 2011-06-30 | 2011-06-30 | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2726507T true PT2726507T (pt) | 2019-02-26 |
Family
ID=46384405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT12729996T PT2726507T (pt) | 2011-06-30 | 2012-06-29 | Anticorpos contra antigéneos celulares especificos da próstata e uso dos mesmos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9200078B2 (OSRAM) |
| EP (2) | EP3505536B1 (OSRAM) |
| JP (4) | JP2014528696A (OSRAM) |
| AU (1) | AU2012277784B2 (OSRAM) |
| CY (1) | CY1121249T1 (OSRAM) |
| DE (1) | DE102011118022B4 (OSRAM) |
| DK (1) | DK2726507T3 (OSRAM) |
| ES (2) | ES2989975T3 (OSRAM) |
| HR (1) | HRP20190289T1 (OSRAM) |
| HU (1) | HUE042008T2 (OSRAM) |
| LT (1) | LT2726507T (OSRAM) |
| PL (1) | PL2726507T3 (OSRAM) |
| PT (1) | PT2726507T (OSRAM) |
| RS (1) | RS58448B1 (OSRAM) |
| SI (1) | SI2726507T1 (OSRAM) |
| SM (1) | SMT201900085T1 (OSRAM) |
| TR (1) | TR201901991T4 (OSRAM) |
| WO (1) | WO2013001065A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| WO2019066093A1 (ko) * | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| AU2021276327A1 (en) * | 2020-05-19 | 2022-12-01 | City Of Hope | Engineered anti-prostate stem cell antigen fusion proteins and uses thereof |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| WO2024233662A2 (en) * | 2023-05-09 | 2024-11-14 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to psca polypeptides |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
| WO1998040403A1 (en) * | 1997-03-10 | 1998-09-17 | The Regents Of The University Of California | Psca: prostate stem cell antigen |
| DK1226177T3 (da) * | 1999-10-29 | 2008-10-06 | Genentech Inc | Antistofsammensætninger mod anti-prostata stamcelle-antigen (PSCA) og anvendelser deraf |
| KR101229731B1 (ko) * | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 cd3-바인더 |
| JP4651663B2 (ja) * | 2004-05-28 | 2011-03-16 | アジェンシス,インコーポレイテッド | Pscaタンパク質に結合する抗体および関連分子 |
| CA2698343C (en) * | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
| BRPI0919840B1 (pt) * | 2008-10-01 | 2023-02-28 | Amgen Research (Munich) Gmbh | Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende |
| US20110142811A1 (en) * | 2009-12-16 | 2011-06-16 | Deutsches Krebsforschungszentrum | Measles virus for the elimination of unwanted cell populations |
| DE102011118022B4 (de) * | 2011-06-30 | 2018-01-18 | Gemoab Monoclonals Gmbh | Antikörper gegen das Prostata-spezifische Stammzellenantigen und dessen Verwendung |
-
2011
- 2011-06-30 DE DE102011118022.6A patent/DE102011118022B4/de not_active Expired - Fee Related
-
2012
- 2012-06-29 SM SM20190085T patent/SMT201900085T1/it unknown
- 2012-06-29 TR TR2019/01991T patent/TR201901991T4/tr unknown
- 2012-06-29 HR HRP20190289TT patent/HRP20190289T1/hr unknown
- 2012-06-29 US US14/129,933 patent/US9200078B2/en active Active
- 2012-06-29 DK DK12729996.4T patent/DK2726507T3/en active
- 2012-06-29 SI SI201231523T patent/SI2726507T1/sl unknown
- 2012-06-29 LT LTEP12729996.4T patent/LT2726507T/lt unknown
- 2012-06-29 ES ES18207370T patent/ES2989975T3/es active Active
- 2012-06-29 PL PL12729996T patent/PL2726507T3/pl unknown
- 2012-06-29 RS RS20190218A patent/RS58448B1/sr unknown
- 2012-06-29 ES ES12729996T patent/ES2711978T3/es active Active
- 2012-06-29 PT PT12729996T patent/PT2726507T/pt unknown
- 2012-06-29 JP JP2014517736A patent/JP2014528696A/ja active Pending
- 2012-06-29 AU AU2012277784A patent/AU2012277784B2/en not_active Ceased
- 2012-06-29 WO PCT/EP2012/062716 patent/WO2013001065A1/de not_active Ceased
- 2012-06-29 EP EP18207370.0A patent/EP3505536B1/de active Active
- 2012-06-29 EP EP12729996.4A patent/EP2726507B1/de active Active
- 2012-06-29 HU HUE12729996A patent/HUE042008T2/hu unknown
-
2017
- 2017-01-12 JP JP2017002983A patent/JP6549622B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-11 CY CY20191100176T patent/CY1121249T1/el unknown
- 2019-06-26 JP JP2019117977A patent/JP6886491B2/ja active Active
-
2021
- 2021-05-13 JP JP2021081553A patent/JP7341185B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RS58448B1 (sr) | 2019-04-30 |
| PL2726507T3 (pl) | 2019-06-28 |
| ES2711978T3 (es) | 2019-05-08 |
| JP6886491B2 (ja) | 2021-06-16 |
| LT2726507T (lt) | 2019-04-10 |
| US20140134155A1 (en) | 2014-05-15 |
| JP2021121201A (ja) | 2021-08-26 |
| AU2012277784B2 (en) | 2015-08-20 |
| SI2726507T1 (sl) | 2019-05-31 |
| EP2726507B1 (de) | 2018-11-21 |
| DE102011118022B4 (de) | 2018-01-18 |
| HRP20190289T1 (hr) | 2019-05-03 |
| JP2014528696A (ja) | 2014-10-30 |
| EP3505536A1 (de) | 2019-07-03 |
| ES2989975T3 (es) | 2024-11-28 |
| DE102011118022A1 (de) | 2013-01-03 |
| DK2726507T3 (en) | 2019-03-11 |
| WO2013001065A1 (de) | 2013-01-03 |
| US9200078B2 (en) | 2015-12-01 |
| JP7341185B2 (ja) | 2023-09-08 |
| JP6549622B2 (ja) | 2019-07-24 |
| HUE042008T2 (hu) | 2019-06-28 |
| EP3505536B1 (de) | 2024-08-07 |
| AU2012277784A1 (en) | 2014-02-06 |
| TR201901991T4 (tr) | 2019-03-21 |
| CY1121249T1 (el) | 2020-05-29 |
| EP2726507A1 (de) | 2014-05-07 |
| EP3505536C0 (de) | 2024-08-07 |
| JP2019193652A (ja) | 2019-11-07 |
| JP2017104113A (ja) | 2017-06-15 |
| SMT201900085T1 (it) | 2019-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288203A (en) | Meditops and Meditop binding antibodies and their use | |
| IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
| SI2726507T1 (sl) | Protitelesa proti antigenu prostatno specifičnih matičnih celic in njihova uporaba | |
| IL259436A (en) | Antibodies against 3angptl and their uses | |
| IL251697A0 (en) | Antibodies against 3erbb and their uses | |
| IL232399A0 (en) | Anti-2fgfr antibodies and their use | |
| EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
| ZA201403264B (en) | Neutralizing gp41 antibodies and their use | |
| GB201115529D0 (en) | Antibodies, uses and methods | |
| GB201115280D0 (en) | Antibodies, uses and methods | |
| IL232213B (en) | Antibody Formulations and Methods | |
| PT2729170T (pt) | Variantes de anticorpos e utilizações das mesmas |